Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
ORAGRAFIN CALCIUM is an oral granule diagnostic agent approved in 1962 by Bracco, used as a radiographic contrast medium for gastrointestinal imaging. The product enables visualization of the GI tract through oral administration, supporting diagnostic procedures. Mechanism of action involves radiopaque calcium compound that enhances contrast in radiographic studies.
Declining product in mature diagnostic imaging market with low competitive pressure (30%), indicating stable but diminishing team resources.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ORAGRAFIN CALCIUM offers limited career growth potential due to its LOE approaching status and minimal linked job openings (0). Roles available are primarily focused on maintenance, compliance, and managed decline rather than expansion or innovation.
Worked on ORAGRAFIN CALCIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.